SWTX Stock Forecast 2025-2026
Distance to SWTX Price Targets
SWTX Price Momentum
🤔 Considering SpringWorks (SWTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest SWTX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, SWTX has a bullish consensus with a median price target of $72.00 (ranging from $63.00 to $87.00). Currently trading at $51.14, the median forecast implies a 40.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Peter Lawson at Barclays, suggesting a 23.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SWTX Analyst Ratings
SWTX Price Target Range
Latest SWTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SWTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Feb 12, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Feb 12, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $77.00 |
| Feb 12, 2025 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $65.00 |
| Jan 8, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $78.00 |
| Nov 20, 2024 | Evercore ISI Group | Cory Kasimov | Outperform | Initiates | $60.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $74.00 |
| Sep 4, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $68.00 |
| Aug 28, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $76.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| May 31, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| May 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $74.00 |
| Mar 6, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $75.00 |
| Feb 29, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $63.00 |
| Feb 26, 2024 | Wedbush | David Nierengarten | Outperform | Maintains | $70.00 |
| Jan 25, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $47.00 |
| Nov 29, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $73.00 |
| Nov 29, 2023 | Goldman Sachs | Corinne Jenkins | Buy | Maintains | $52.00 |
SpringWorks Therapeutics, Inc. (SWTX) Competitors
The following stocks are similar to SpringWorks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SpringWorks Therapeutics, Inc. (SWTX) Financial Data
SpringWorks Therapeutics, Inc. has a market capitalization of $3.83B with a P/E ratio of 0.0x. The company generates $191.59M in trailing twelve-month revenue with a -134.7% profit margin.
Revenue growth is +1,030.0% quarter-over-quarter, while maintaining an operating margin of -132.2% and return on equity of -46.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
SpringWorks Therapeutics, Inc. (SWTX) Business Model
About SpringWorks Therapeutics, Inc.
Develops innovative medicines for rare diseases.
SpringWorks Therapeutics generates revenue by developing and commercializing therapies targeted at rare diseases and genomics-driven oncology. The company collaborates with partners to enhance its research capabilities and expedite the development of its product pipeline, focusing on addressing significant unmet medical needs.
The biopharmaceutical sector, particularly in rare diseases, is increasingly crucial, as it addresses specific patient populations with limited treatment options. SpringWorks' strategic emphasis on both innovation and optimization of therapies positions it as a vital player in this evolving market, highlighting its potential for growth and impact.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
368
CEO
Mr. Saqib Islam J.D.
Country
United States
IPO Year
2019
Website
www.springworkstx.comSpringWorks Therapeutics, Inc. (SWTX) Latest News & Analysis
SpringWorks Therapeutics reports $172M in 2024 revenues from Ogsiveo, its treatment for desmoid tumors. Gomekli is the first FDA-approved MEK inhibitor for NF1-plexiform neurofibromas.
SpringWorks Therapeutics’ strong revenue from Ogsiveo and FDA approval of Gomekli highlight its growth potential in niche markets, enhancing investor confidence in its future performance.
SWTX's revenue is boosted by Ogsiveo for desmoid tumors, and the FDA approval of Gomekli for a rare tumor expands its commercial offerings.
SWTX's revenue growth from Ogsiveo and new FDA approval for Gomekli enhances its market position and diversifies risk, potentially boosting shareholder value and attracting investment.
SWTX's Q4 2024 results were mixed, but the launch of its newly approved desmoid tumor drug, Ogsiveo, showed strong performance.
Mixed results may signal volatility for SWTX, but strong launch of Ogsiveo could drive future revenue and growth, impacting stock performance and investor sentiment.
For Q4 2024, OGSIVEO® (nirogacestat) reported U.S. net product revenues of $61.5 million, totaling $172.0 million for the full year.
Strong revenue figures for OGSIVEO® indicate robust market demand and potential for future growth, impacting the company’s financial health and investor sentiment positively.
SpringWorks Therapeutics (SWTX) reported a quarterly loss of $1.04 per share, worse than the estimated loss of $0.72, compared to a loss of $1.44 per share a year prior.
Wider-than-expected losses may signal ongoing financial struggles for SpringWorks Therapeutics, potentially impacting stock performance and investor confidence.
SpringWorks Therapeutics is launching an educational campaign with patient advocate Jennifer Fisher to raise awareness about desmoid tumors and encourage patients to seek specialized treatment.
The collaboration between SpringWorks Therapeutics and a patient advocate may enhance brand visibility, potentially increasing patient engagement and driving demand for their treatments in a niche market.
Frequently Asked Questions About SWTX Stock
What is SpringWorks Therapeutics, Inc.'s (SWTX) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, SpringWorks Therapeutics, Inc. (SWTX) has a median price target of $72.00. The highest price target is $87.00 and the lowest is $63.00.
Is SWTX stock a good investment in 2025?
According to current analyst ratings, SWTX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $51.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SWTX stock?
Wall Street analysts predict SWTX stock could reach $72.00 in the next 12 months. This represents a 40.8% increase from the current price of $51.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is SpringWorks Therapeutics, Inc.'s business model?
SpringWorks Therapeutics generates revenue by developing and commercializing therapies targeted at rare diseases and genomics-driven oncology. The company collaborates with partners to enhance its research capabilities and expedite the development of its product pipeline, focusing on addressing significant unmet medical needs.
What is the highest forecasted price for SWTX SpringWorks Therapeutics, Inc.?
Price targets from Wall Street analysts for SWTX are not currently available. The stock is trading at $51.14.
What is the lowest forecasted price for SWTX SpringWorks Therapeutics, Inc.?
The lowest price target for SWTX is $63.00 from Peter Lawson at Barclays, which represents a 23.2% increase from the current price of $51.14.
What is the overall SWTX consensus from analysts for SpringWorks Therapeutics, Inc.?
The overall analyst consensus for SWTX is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $72.00.
How accurate are SWTX stock price projections?
Stock price projections, including those for SpringWorks Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
